Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

PTGX

Protagonist Therapeutics Inc

Apr 15 • 04:00PM ET

26.58

Dollar change -0.46
Percentage change -1.70	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB IWO SCHA VTWO LABU IWN VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.48	Insider Own	5.96%	Shs Outstand	57.71M	Perf Week	-5.38%
Market Cap	1.55B	Forward P/E	-	EPS next Y	-0.81	Insider Trans	-4.77%	Shs Float	54.80M	Perf Month	-6.24%
Income	-78.95M	PEG	-	EPS next Q	1.19	Inst Own	95.65%	Short Float	6.28%	Perf Quarter	2.63%
Sales	60.00M	P/S	25.81	EPS this Y	194.96%	Inst Trans	-9.36%	Short Ratio	4.95	Perf Half Y	72.93%
Book/sh	5.83	P/B	4.56	EPS next Y	-161.03%	ROA	-26.05%	Short Interest	3.44M	Perf Year	36.24%
Cash/sh	5.86	P/C	4.53	EPS next 5Y	-	ROE	-28.59%	52W Range	13.72 - 33.34	Perf YTD	15.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.38%	ROI	-23.45%	52W High	-20.28%	Beta	2.06
Dividend TTM	-	Quick Ratio	16.71	Sales past 5Y	2462.45%	Gross Margin	94.48%	52W Low	93.73%	ATR (14)	1.13
Dividend Ex-Date	-	Current Ratio	16.71	EPS Y/Y TTM	43.46%	Oper. Margin	-156.09%	RSI (14)	38.28	Volatility	3.71% 3.65%
Employees	112	Debt/Eq	0.00	Sales Y/Y TTM	125.73%	Profit Margin	-131.59%	Recom	1.17	Target Price	43.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	163.72%	Payout	-	Rel Volume	0.64	Prev Close	27.04
Sales Surprise	0.00%	EPS Surprise	720.90%	Sales Q/Q	-	Earnings	Feb 28 BMO	Avg Volume	694.11K	Price	26.58
SMA20	-5.85%	SMA50	-6.73%	SMA200	22.27%	Trades		Volume	440,981	Change	-1.70%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-30-23	Initiated	CapitalOne	Overweight	$32
May-25-23	Resumed	Jefferies	Buy	$30 → $40
Aug-25-22	Initiated	JMP Securities	Mkt Outperform	$21
Feb-11-22	Initiated	BTIG Research	Buy	$55
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight	$49 → $55
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform	$40
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral	$60 → $49
May-24-21	Initiated	Northland Capital	Outperform	$42
May-24-21	Initiated	JMP Securities	Mkt Outperform	$48
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight	$53
Sep-18-20	Reiterated	H.C. Wainwright	Buy	$28 → $33
Jul-15-20	Initiated	Jefferies	Buy	$27
May-18-20	Reiterated	H.C. Wainwright	Buy	$23 → $28
Jul-08-19	Initiated	H.C. Wainwright	Buy	$23
May-09-19	Upgrade	Stifel	Hold → Buy	$11 → $17
Dec-06-18	Initiated	Nomura	Buy	$13
Jan-29-18	Initiated	Stifel	Buy	$32
Jul-21-17	Initiated	BTIG Research	Buy	$36

Show Previous Ratings

Apr-05-24 12:00PM	All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy (Zacks)
Apr-03-24 01:52AM	Protagonist Therapeutics Inc CEO Sells 25,000 Shares (GuruFocus.com)
Mar-26-24 07:00AM	Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data (ACCESSWIRE)
Mar-18-24 09:55AM	Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet (Zacks)
07:00AM	Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda (ACCESSWIRE)
07:00AM	Loading…
Mar-11-24 07:00AM	Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year (ACCESSWIRE)
Mar-06-24 04:05PM	Protagonist Therapeutics to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Mar-01-24 12:20PM	Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy? (Zacks) +5.83%
12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
12:00PM	Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice (Zacks)
09:55AM	Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade (Zacks)
08:50AM	Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why (Zacks)
Feb-27-24 04:38PM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-21-24 05:00PM	New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera (ACCESSWIRE)
04:05PM	Loading…
Feb-20-24 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Feb-15-24 03:13AM	Steven Cohen Adjusts Position in Protagonist Therapeutics Inc (GuruFocus.com)
Feb-07-24 05:00PM	New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study (ACCESSWIRE)
Feb-02-24 01:03PM	Protagonist (PTGX) Up 14% on Licensing Deal With Takeda (Zacks) -7.12%
Feb-01-24 06:35AM	Takeda pays $300M to license Protagonist drug for blood disorder (BioPharma Dive) +14.03%
Jan-31-24 04:05PM	Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset (ACCESSWIRE)
Jan-29-24 07:30AM	Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024 (ACCESSWIRE) +6.78%
Jan-12-24 03:02AM	Insider Suneel Gupta Sells 5,000 Shares of Protagonist Therapeutics Inc (PTGX) (GuruFocus.com) +6.06%
Jan-03-24 07:30AM	Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (ACCESSWIRE)
Dec-16-23 11:01AM	Insider Sell Alert: CEO PATEL DINESH V PH D Sells 75,000 Shares of Protagonist Therapeutics Inc ... (GuruFocus.com)
Dec-13-23 07:30AM	Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis (ACCESSWIRE)
Dec-12-23 09:04AM	Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals (ACCESSWIRE)
Nov-27-23 09:00AM	Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib (ACCESSWIRE)
Nov-16-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
05:50AM	Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On (Motley Fool)
03:55PM	Loading…
Nov-09-23 03:55PM	Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM) (ACCESSWIRE) -5.82%
09:55AM	Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 141.08% as Wall Street Analysts Expect? (Zacks)
Nov-04-23 05:42AM	Protagonist Therapeutics Inc (PTGX) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-02-23 06:24PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
09:05AM	Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting (ACCESSWIRE)
Nov-01-23 04:05PM	Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis (ACCESSWIRE)
07:30AM	Protagonist Therapeutics to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Oct-30-23 04:05PM	Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors (ACCESSWIRE)
Oct-09-23 07:00AM	Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications (ACCESSWIRE)
Oct-03-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Sep-05-23 07:30AM	Protagonist Therapeutics to Present at Upcoming Investor Conferences (ACCESSWIRE)
Aug-16-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Aug-09-23 07:00AM	Protagonist Receives $34 Million from Warrant Exercises (ACCESSWIRE)
Aug-03-23 04:48PM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-18-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Jul-05-23 09:33AM	Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment (Benzinga)
Jul-04-23 03:30AM	Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis (ACCESSWIRE)
Jun-30-23 08:50AM	Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-15-23 09:55AM	Wall Street Analysts Predict a 25.35% Upside in Protagonist Therapeutics (PTGX): Here's What You Should Know (Zacks)
Jun-13-23 08:50AM	Here's Why Momentum in Protagonist Therapeutics (PTGX) Should Keep going (Zacks)
Jun-09-23 08:05AM	Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of Rusfertide in PV (ACCESSWIRE)
Jun-06-23 07:30AM	Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress (ACCESSWIRE)
Jun-01-23 04:01PM	Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference (ACCESSWIRE) +5.45%
May-26-23 09:55AM	How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 38.01% (Zacks)
May-12-23 03:14PM	Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment (Benzinga)
07:00AM	Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 (PR Newswire)
May-11-23 04:05PM	Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference (PR Newswire)
10:17AM	Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association (PR Newswire)
May-05-23 04:03PM	Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm (Investor's Business Daily) +5.13%
May-04-23 05:02PM	Protagonist Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:05PM	Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Apr-20-23 09:51PM	Why Shares of Protagonist Therapeutics Rose This Week (Motley Fool)
Apr-17-23 06:35AM	Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Yet to Catch Up With Its Share Price (Simply Wall St.) +10.03%
Apr-04-23 10:45PM	Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock (ACCESSWIRE) -5.57%
04:11PM	Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock (ACCESSWIRE)
Mar-21-23 03:49AM	Strength Seen in Nurix Therapeutics, Inc. (NRIX): Can Its 5.7% Jump Turn into More Strength? (Zacks)
Mar-20-23 06:08AM	Analysts Just Made A Major Revision To Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts (Simply Wall St.)
Mar-17-23 06:06AM	Protagonist Therapeutics (NASDAQ:PTGX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Mar-15-23 04:01PM	Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
01:39PM	Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study (Benzinga)
07:30AM	Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera (ACCESSWIRE)
Mar-09-23 11:14AM	Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More (Zacks)
Mar-08-23 12:19PM	Protagonist (PTGX) Up on Positive Results From FRONTIER Study (Zacks)
10:02AM	Protagonist Therapeutics (PTGX) Soars 51.9%: Is Further Upside Left in the Stock? (Zacks)
Mar-07-23 11:54AM	Why Protagonist Therapeutics Shares Are Trading Higher Today (Benzinga) +51.91%
08:00AM	Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis (PR Newswire)
Jan-25-23 03:24AM	Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last? (Zacks)
Jan-14-23 07:14AM	Are Investors Undervaluing Protagonist Therapeutics, Inc. (NASDAQ:PTGX) By 50%? (Simply Wall St.)
Dec-21-22 04:05PM	Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire) +5.05%
Dec-05-22 09:55AM	Can Protagonist Therapeutics (PTGX) Climb 323% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-01-22 07:05AM	Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit (PR Newswire)
Nov-16-22 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (PR Newswire)
Nov-11-22 09:55AM	How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 337% (Zacks)
05:11AM	Protagonist Therapeutics Third Quarter 2022 Earnings: US$0.64 loss per share (vs US$0.70 loss in 3Q 2021) (Simply Wall St.)
Nov-08-22 04:05PM	Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Nov-03-22 09:16AM	Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting (PR Newswire)
Oct-12-22 06:10AM	Investors in Protagonist Therapeutics (NASDAQ:PTGX) have unfortunately lost 74% over the last year (Simply Wall St.)
Oct-05-22 09:55AM	Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 322% as Wall Street Analysts Expect? (Zacks)
Oct-02-22 07:39AM	Stocks Are Looking Increasingly Cheap, Says J.P. Morgan; Here Are 2 Names to Consider (TipRanks)
Sep-23-22 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Sep-20-22 05:40PM	Protagonist Therapeutics Reports Granting of Inducement Award (PR Newswire)
Aug-10-22 09:55AM	How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 302% (Zacks)
Aug-04-22 07:15PM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Jul-19-22 07:00AM	Protagonist Therapeutics Reports Granting of Inducement Award (PR Newswire) +7.22%
Jul-18-22 06:11AM	Novavax (NVAX) Soars 5.4%: Is Further Upside Left in the Stock? (Zacks)
Jul-17-22 09:11AM	We're Hopeful That Protagonist Therapeutics (NASDAQ:PTGX) Will Use Its Cash Wisely (Simply Wall St.)
Jun-01-22 04:05PM	Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference (PR Newswire)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PATEL DINESH V PH D	President and CEO	Apr 01 '24	Sale	28.31	25,000	707,750	549,590	Apr 02 08:29 PM
SELICK HAROLD E	Director	Mar 07 '24	Option Exercise	1.89	6,490	12,266	27,996	Mar 11 08:00 PM
Ali Asif	Chief Financial Officer	Mar 01 '24	Option Exercise	12.17	12,000	146,040	52,645	Mar 01 08:45 PM
Waddill William D.	Director	Mar 01 '24	Option Exercise	6.09	12,975	79,018	24,975	Mar 01 08:45 PM
PATEL DINESH V PH D	President and CEO	Mar 01 '24	Sale	31.62	30,000	948,600	574,590	Mar 01 08:46 PM
Ali Asif	Chief Financial Officer	Mar 01 '24	Sale	32.24	14,248	459,318	38,397	Mar 01 08:45 PM
Waddill William D.	Director	Mar 01 '24	Sale	31.34	12,975	406,636	12,000	Mar 01 08:45 PM
Ali Asif	Chief Financial Officer	Feb 29 '24	Sale	30.69	9,939	305,048	40,645	Mar 01 08:45 PM
Gupta Suneel	Chief Development Officer	Jan 09 '24	Option Exercise	7.38	5,000	36,900	192,567	Jan 11 08:00 PM
Gupta Suneel	Chief Development Officer	Jan 09 '24	Sale	25.00	5,000	125,000	187,567	Jan 11 08:00 PM
PATEL DINESH V PH D	President and CEO	Dec 13 '23	Sale	20.08	75,000	1,506,000	534,347	Dec 15 04:30 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 15 '23	Sale	16.24	1,848	30,012	22,527	Jan 04 08:09 PM
Gupta Suneel	Chief Development Officer	Oct 19 '23	Option Exercise	7.38	20,000	147,600	168,317	Oct 23 04:31 PM
PATEL DINESH V PH D	President and CEO	Oct 18 '23	Option Exercise	4.21	6,000	25,260	609,347	Oct 19 04:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTGX

Protagonist Therapeutics Inc

Upgrade your FINVIZ experience